Protalix Biotherapeutics, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
AMEX
MAK Capital Fund LP, MAK Capital One L.L.C., and Michael A. Kaufman have jointly reported a 5.8% beneficial ownership stake in Protalix BioTherapeutics, Inc.